Browse drugs

…patients (n=313) were randomised (1:1:1) to receive intravenous guselkumab 200 or 400 mg or placebo at weeks 0, 4, and 8. Colon biopsy sam…

…-23 signaling. Front. Immunol. 2025;16:1532852.Rubin DT, et al. Guselkumab in patients with moderately to severely active ulcerative colit…

…Introduction Guselkumab (GUS) is a dual-acting IL-23p19 subunit inhibitor that potently…

…mg SC q4w maintenance vs PBO also achieved histologic response (GUS 100 mg SC q8w 49.5% and GUS 200 mg SC q4w 63.6% vs 10.6% PBO), …

…8 pts allocated 1:1:1 to GUS 400 mg SC every 4 weeks (q4w) (×3)→GUS 200 mg SC q4w (N=140), GUS 400 mg SC q4w (×3)→GUS 100 mg SC eve…

… full analysis set, 113 received GUS 100mg SC Q8W, 115 received GUS 200mg SC Q4W, and 58 received PBO. 91.3% completed the 24 weeks…

… SC maintenance (100 mg q8w or 200 mg q4w). GRAVITI assessed SC GUS induction (400 mg at W0, W4, and W8) and the same GUS maintenan…

…Objective Guselkumab (GUS) is a dual-acting IL-23p19 inhibitor that neutralises IL-2…

… (≤12 [IV: GUS=43%, PBO=21%; SC: GUS=52%, PBO=24%] and >12 [IV: GUS=53% vs PBO=16%; SC: GUS=62% vs PBO=18%]), baseline CRP (≤3mg/L …

…lomatous prostatitis and the only reported case of a patient on guselkumab immunotherapy.…

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…generalised granuloma annulare (GA) after 3 years of successful ustekinumab therapy for severe palmoplantar psoriasis. Ustekinumab, an inte…